NCT03101267已完成2 期
Phase 2 Dose-finding Study of ASP4070 - A Randomized, Double-blind, Placebo-controlled, Dose-finding Study in Patients With Cedar Pollinosis Using an Environmental Exposure Chamber -
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 150
- 试验地点
- 1
- 主要终点
- Change From Pre-Exposure in Mean Total 3 Nasal Symptom Score (3TNSS) 120 to 180 Minutes After Start of Cedar Pollen Exposure on Day 183
研究概览
简要总结
The objective of this study was to evaluate the efficacy, safety, and dose-response of ASP4070 vaccinated in patients with cedar pollinosis.
详细描述
Subjects were vaccinated with ASP4070 or placebo at 2 week intervals. Clinical symptoms were evaluated after cedar pollen exposure in a chamber at 4, 8 and 12 weeks after the last vaccination to identify the timing of the onset of therapeutic effect.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 20 Years 至 64 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject who has exhibited symptoms of cedar pollinosis, consisting of nasal symptoms (sneezing, nasal discharge or nasal obstruction) and eye symptoms (itchy eyes or watery eyes) during the pollen dispersal seasons in 2016 and 2017
- •Subject who is positive for the Japanese red cedar (JRC) pollen-specific serum IgE antibody test
- •At screening, subject whose score has worsened compared to baseline over 120 to 180 minutes after cedar pollen exposure in a chamber
排除标准
- •Subject who has positive the test result of serum IgE antibody specific to other antigen than JRC pollen at screening
- •Subject who has received specific immunotherapy (including desensitization therapy) for cedar pollinosis in the past
- •Subject who has received specific or non-specific immunotherapy within 5 years prior to screening
- •Subject who has received laser therapy or surgery for the treatment of nasal symptoms within 3 years prior to screening.
- •Subject who has a history of allergic reactions such as anaphylactic shock and exanthema generalized caused by food and/or medical products in the past
- •Subject who has a positive test result for hepatitis B surface (HBs) antigen or anti-hepatitis C virus (HCV) antibody
- •Subject who has nasal disease that may interfere with the evaluation
- •Subject who has autoimmune disease or other serious primary disease
- •Subject who was diagnosed with immunodeficiency in the past
- •Subject who has a complication of seasonal allergic rhinitis (due to allergens other than Japanese cedars or cypress), perennial allergic rhinitis, rhinitis medicamentosa, or non-allergic rhinitis that requires medical treatment
- •Subject who has a complication of cardiovascular disease
- •Subject who has a complication of hepatic disease
- •Subject who has a complication of renal disease
- •Subject who has a complication of respiratory disease
- •Subject has a complication of malignant tumor or has been diagnosed with or has received treatment for malignant tumor within 5 years prior to the first vaccination of the study drug
- •Subject who was diagnosed with schizophrenia, other mental conditions
- •Subject who has a complication that may have an impact on the results of the local or systemic reaction
- •Subject who has received a vaccination of Cry j 2-LAMP vaccine
- •Subject who has participated in a clinical study of ASP4070 and received a vaccination of the study drug.
研究组 & 干预措施
ASP4070 4 mg
Experimental
Participants received ASP4070 4 mg 8 times by intradermal vaccination at 14-day intervals.
干预措施: ASP4070 (Drug)
ASP4070 1 mg
Experimental
Participants received ASP4070 1 mg 8 times by intradermal vaccination at 14-day intervals.
干预措施: ASP4070 (Drug)
Placebo
Placebo Comparator
Participants received Placebo 8 times by intradermal vaccination at 14-day intervals.
干预措施: Placebo (Drug)
结局指标
主要结局
Change From Pre-Exposure in Mean Total 3 Nasal Symptom Score (3TNSS) 120 to 180 Minutes After Start of Cedar Pollen Exposure on Day 183
时间窗: Day 183 at pre-exposure and 120 to 180 minutes after the start of cedar pollen exposure (5 samples 15 minutes apart)
Participants were assessed for each symptom (sneezing, nasal discharge and nasal congestion) using the following score every 15 minutes from before cedar pollen exposure until 180 minutes after cedar pollen exposure. 0: None (no symptoms) 1. Mild (symptoms present but easily tolerated) 2. Moderate (awareness of symptoms; bothersome, but tolerable) 3. Severe (definite awareness of symptoms; difficult to tolerate, but does not interfere with the activities of daily living) 4. Very severe (difficult to tolerate and interferes with the activities of daily living). 3TNSS was a summed score of each symptom, and mean of 3TNSS at 120 to 180 min is the average of 5 timepoints of 3TNSS score, which ranged from 0 to 12. Higher 3TNSS score indicated greater disease activity.
次要结局
- Change From Pre-Exposure in Sneezing Score 120 to 180 Minutes After Cedar Pollen Exposure(Pre-exposure and 120-180 minutes after the start of pollen exposure (5 samples 15 minutes apart) on Days 127, 155, and 183)
- Change From Pre-Exposure in Mean Itchy Eyes Score 120 to 180 Minutes After Cedar Pollen Exposure(Pre-exposure and 120-180 minutes after the start of pollen exposure (5 samples 15 minutes apart) on Days 127, 155, and 183)
- Change From Pre-Exposure in Mean Total 4 Nasal Symptom Score (4TNSS) 120 to 180 Minutes After Cedar Pollen Exposure(Pre-exposure and 120-180 minutes after the start of pollen exposure (5 samples 15 minutes apart) on Days 127, 155, and 183)
- Amount of Nasal Discharge Per 30 Minutes During Cedar Pollen Exposure(Day 127: 0-30 min, 30-60 min, 60-90 min, 90-120 min, 120-150 min, 150-180 min, Day 155: 0-30 min, 30-60 min, 60-90 min, 90-120 min, 120-150 min, 150-180 min, Day 183: 0-30 min, 30-60 min, 60-90 min, 90-120 min, 120-150 min, 150-180 min)
- Change From Pre-Exposure in Mean Total Non-Nasal Symptom Score (TNNSS) 120 to 180 Minutes After Cedar Pollen Exposure(Pre-exposure and 120-180 minutes after the start of pollen exposure (5 samples 15 minutes apart) on Days 127, 155, and 183)
- Change From Pre-Exposure in Mean Nasal Congestion Score 120 to 180 Minutes After Cedar Pollen Exposure(Pre-exposure and 120-180 minutes after the start of pollen exposure (5 samples 15 minutes apart) on Days 127, 155, and 183)
- Change From Pre-Exposure in Mean Itchy Nose Score 120 to 180 Minutes After Cedar Pollen Exposure(Pre-exposure and 120-180 minutes after the start of pollen exposure (5 samples 15 minutes apart) on Days 127, 155, and 183)
- Time to Occurrence of Nasal or Eye Symptom From Start of Cedar Pollen Exposure(Days 127, 155 and 183, from the start of cedar pollen exposure for up to 180 minutes)
- Sneezing Count Per 30 Minutes During Cedar Pollen Exposure(Day 127: 0-30 min, 30-60 min, 60-90 min, 90-120 min, 120-150 min, 150-180 min, Day 155: 0-30 min, 30-60 min, 60-90 min, 90-120 min, 120-150 min, 150-180 min, Day 183: 0-30 min, 30-60 min, 60-90 min, 90-120 min, 120-150 min, 150-180 min)
- Change From Pre-Exposure in Nasal Discharge Score 120 to 180 Minutes After Cedar Pollen Exposure(Pre-exposure and 120-180 minutes after the start of pollen exposure (5 samples 15 minutes apart) on Days 127, 155, and 183)
- Change From Pre-Exposure in Mean Total 6 Symptom Score (6TSS) 120 to 180 Minutes After Cedar Pollen Exposure(Pre-exposure and 120-180 minutes after the start of pollen exposure (5 samples 15 minutes apart) on Days 127, 155, and 183)
- Change From Pre-Exposure in Mean Watery Eyes Score 120 to 180 Minutes After Cedar Pollen Exposure(Pre-exposure and 120-180 minutes after the start of pollen exposure (5 samples 15 minutes apart) on Days 127, 155, and 183)
- Change From Pre-Exposure in Total 5 Symptom Score (5TSS) 120 to 180 Minutes After Cedar Pollen Exposure(Pre-exposure and 120-180 minutes after the start of pollen exposure (5 samples 15 minutes apart) on Days 127, 155, and 183)
- Number of Participants With Adverse Events (AE) During the Primary Study Period(From first dose of study drug up to the end of primary study period (up to 7 days after Day 183))
- Number of Participants With Serious Adverse Events (SAE) During the Long-Term Safety Follow-Up Period(Up to 9 months after the end of primary study period (primary study period was up to 7 days after Day 183))
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A Study to Assess the Effectiveness and Safety of Different Doses of ASP1707 Compared to Placebo for Endometriosis Associated Pelvic PainEndometriosisNCT01767090Astellas Pharma Europe B.V.912
已完成
2 期
A Study to Evaluate Dose Responses of Efficacy and Safety of ASP0456 in Patient With Chronic ConstipationChronic ConstipationNCT02425722Astellas Pharma Inc383
已完成
2 期
Multiple Dose Safety and Efficacy Study Evaluating CNS 7056 Versus Midazolam in Patients Undergoing ColonoscopySedationNCT01145222Paion UK Ltd.162
已完成
1 期
A Study to Assess the Safety, Tolerability and Immunogenicity of ASP3772, a Pneumococcal Vaccine, in Toddlers 12 to 15 Months of Age in Comparison to an Active ComparatorHealthy VolunteersPneumococcal DiseaseNCT04525599Affinivax, Inc.75
终止
1 期
Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal MelanomaUveal MelanomaAcute Myeloid LeukemiaMyelodysplastic SyndromeNCT02743611Bellicum Pharmaceuticals4